leuprolide acetate for depot suspension / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 138 Diseases   94 Trials   94 Trials   2090 News 


«12...1617181920212223242526...3233»
  • ||||||||||  progesterone / Generic mfg., leuprolide acetate for depot suspension / Generic mfg.
    Trial completion date, Trial primary completion date:  Metabolic Study of Women With Polycystic Ovary Syndrome and Sleep Apnea (clinicaltrials.gov) -  Apr 14, 2020   
    P=N/A,  N=80, Active, not recruiting, 
    Recruiting --> Suspended Trial completion date: Jan 2019 --> Jan 2021 | Trial primary completion date: Jan 2019 --> Jan 2021
  • ||||||||||  Xtandi (enzalutamide capsule) / Pfizer, Astellas
    Trial completion date:  Trial of Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate Cancer (clinicaltrials.gov) -  Apr 8, 2020   
    P2,  N=11, Active, not recruiting, 
    Trial completion date: Dec 2019 --> Dec 2021 | Trial primary completion date: Dec 2019 --> Dec 2020 Trial completion date: Jun 2022 --> Jun 2020
  • ||||||||||  leuprolide acetate for depot suspension / Generic mfg.
    Trial suspension:  Brown Adipose Tissue Activity in Pre- and Postmenopausal Women (clinicaltrials.gov) -  Apr 6, 2020   
    P=N/A,  N=72, Suspended, 
    Trial completion date: Jun 2022 --> Jun 2020 Recruiting --> Suspended
  • ||||||||||  Erleada (apalutamide) / J&J
    Trial termination:  A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer (clinicaltrials.gov) -  Mar 30, 2020   
    P2,  N=9, Terminated, 
    Recruiting --> Active, not recruiting | N=900 --> 554 | Trial completion date: Oct 2021 --> Apr 2021 | Trial primary completion date: Oct 2021 --> Apr 2021 Active, not recruiting --> Terminated; Safety concerns
  • ||||||||||  Livial (tibolone) / Organon
    Trial completion date, Trial primary completion date:  Psychological Impact of Amenorrhea in Women With Endometriosis (clinicaltrials.gov) -  Mar 24, 2020   
    P4,  N=50, Not yet recruiting, 
    Not yet recruiting --> Recruiting Trial completion date: May 2020 --> Dec 2020 | Trial primary completion date: Jan 2020 --> Sep 2020
  • ||||||||||  Xtandi (enzalutamide capsule) / Pfizer, Astellas
    Trial completion date, Trial primary completion date:  Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer (clinicaltrials.gov) -  Mar 16, 2020   
    P2,  N=9, Active, not recruiting, 
    Trial completion date: May 2020 --> Dec 2020 | Trial primary completion date: Jan 2020 --> Sep 2020 Trial completion date: Dec 2019 --> Jun 2020 | Trial primary completion date: Dec 2019 --> Jun 2020
  • ||||||||||  Lupron Depot (leuprorelin depot) / AbbVie, Takeda
    Recurrent Pneumothorax in a Young Female (PENNSYLVANIA CONVENTION CENTER, Hall D-E (200 Level), Area H) -  Mar 15, 2020 - Abstract #ATS2020ATS_9263;    
    She has tolerated therapy with no recurrence of pneumothorax.This case showcases the difficulty of diagnosis even though there was clinical suspicion and highlights the need for aggressive hormonal suppression to effectively treat this condition. Many patients do not have classic presentation and there is no definitive lab or tissue confirmation, so often this is a diagnosis of exclusion.
  • ||||||||||  Lupron Depot (leuprorelin depot) / AbbVie, Takeda, minocycline / Generic mfg., Cubicin (daptomycin) / Merck (MSD)
    A Case of Drug-Induced Acute Eosinophilic Pneumonia (PENNSYLVANIA CONVENTION CENTER, Hall D-E (200 Level), Area G) -  Mar 15, 2020 - Abstract #ATS2020ATS_7868;    
    To the best of our knowledge, there have only been 37 cases that had diagnostic procedures which confirmed daptomycin as a cause of AEP. Although this is a rare disease, if it is promptly identified and treated, the outcome is excellent with low recurrence rate.
  • ||||||||||  tranexamic acid / Generic mfg., Lupron Depot (leuprorelin depot) / AbbVie, Takeda, bicalutamide / Generic mfg.
    Critical Anemia and Disseminated Intravascular Coagulation with Excessive Fibrinolysis in Prostate Cancer (PENNSYLVANIA CONVENTION CENTER, Hall D-E (200 Level), Area G) -  Mar 15, 2020 - Abstract #ATS2020ATS_5437;    
    Administration of antifibrinolytic agent TXA while controversial is used to directly treat the excessive fibrinolysis. This strategy should be considered in patients requiring critical care treatment for life threatening fibrinolytic disease.
  • ||||||||||  leuprolide acetate for depot suspension / Generic mfg.
    Trial completion:  The Effects of Reproductive Hormones on Mood and Behavior (clinicaltrials.gov) -  Mar 5, 2020   
    P=N/A,  N=124, Completed, 
    This strategy should be considered in patients requiring critical care treatment for life threatening fibrinolytic disease. Recruiting --> Completed
  • ||||||||||  Estrace (estradiol) / AbbVie
    Enrollment open:  Neurobiology of Bulimia Nervosa (clinicaltrials.gov) -  Feb 24, 2020   
    P2,  N=15, Recruiting, 
    N=66 --> 0 | Not yet recruiting --> Withdrawn Not yet recruiting --> Recruiting
  • ||||||||||  Eligard (leuprolide acetate) / TOLMAR, Astellas, Sanofi
    Journal:  The Use of Leuprolide Acetate in the Management of High-Risk Sex Offenders. (Pubmed Central) -  Feb 14, 2020   
    Both treated groups of sexual offenders recidivated at substantially lower rates than predicted by the Static-99R. Currently, this study represents the only, long-term outcome study on Lupron administration using officially recorded recidivism as the primary dependent measure.
  • ||||||||||  Estrace (estradiol) / AbbVie
    Enrollment open, Trial initiation date:  Characterizing the Neural Substrates of Irritability in Women: an Experimental Neuroendocrine Model (clinicaltrials.gov) -  Feb 12, 2020   
    P2,  N=30, Recruiting, 
    Currently, this study represents the only, long-term outcome study on Lupron administration using officially recorded recidivism as the primary dependent measure. Not yet recruiting --> Recruiting | Initiation date: Aug 2019 --> Jan 2020
  • ||||||||||  leuprolide acetate for depot suspension / Generic mfg.
    Trial completion, Phase classification, Enrollment change:  A Treatment Study for Premenstrual Syndrome (PMS) (clinicaltrials.gov) -  Feb 10, 2020   
    P1,  N=64, Completed, 
    Not yet recruiting --> Recruiting | Initiation date: Aug 2019 --> Jan 2020 Phase classification: P=N/A --> P1 | N=100 --> 64 | Recruiting --> Completed
  • ||||||||||  acetazolamide / Generic mfg., Lupron Depot (leuprorelin depot) / AbbVie, Takeda, Eligard (leuprolide acetate) / TOLMAR, Astellas, Sanofi
    A Rare Endocrine Cause of Pseudotumor Cerebri (ENDOExpo) -  Feb 7, 2020 - Abstract #ENDO2020ENDO_1759;    
    He received Lupron Depot® 7.5 mg intramuscularly for 4 doses, then 22.5 mg intramuscular every 13 weeks thereafter... This case highlights that patients on GnRH agonist therapy are at risk for pseudotumor cerebri, and we recommend periodic ophthalmologic surveillance.
  • ||||||||||  Erleada (apalutamide) / J&J
    Trial completion date, Trial primary completion date:  c15-164: AASUR in High Risk Prostate Cancer (clinicaltrials.gov) -  Feb 7, 2020   
    P2,  N=64, Active, not recruiting, 
    This case highlights that patients on GnRH agonist therapy are at risk for pseudotumor cerebri, and we recommend periodic ophthalmologic surveillance. Trial completion date: May 2020 --> May 2021 | Trial primary completion date: May 2020 --> May 2021
  • ||||||||||  Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date, Surgery:  PersonaLized neoAdjuvant Strategy ER Positive and HER2 Negative Breast Cancer TO Increase BCS Rate (clinicaltrials.gov) -  Feb 5, 2020   
    P2,  N=122, Recruiting, 
    Trial completion date: May 2020 --> May 2021 | Trial primary completion date: May 2020 --> May 2021 Not yet recruiting --> Recruiting | Trial completion date: May 2025 --> Dec 2025 | Initiation date: May 2019 --> Nov 2019 | Trial primary completion date: May 2021 --> Dec 2021